<DOC>
	<DOCNO>NCT02917031</DOCNO>
	<brief_summary>This 24 week , multicenter , randomize , double-blind , parallel group , placebo-controlled study investigate effect saxagliptin sitagliptin cardiac dimension function patient type 2 diabetes ( T2DM ) mellitus heart failure ( HF ) .</brief_summary>
	<brief_title>Mechanistic Evaluation Glucose-lowering Strategies Patients With Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Male female , age ≥18 year time consent Heart failure LVEF ≤45 % within last 6 month , elevate NTproBNP ( &gt; 600 pg/mL ) , stable dos HF medication increase decreased ≥8 week prior screen T2DM HbA1c ≥7.0 % ≤9.0 % ( HbA1c ≥7.5 % ≤9.0 % patient treated sulfonylurea agent ) stable dos diabetes medication increase decreased ≥8 week prior screen Normal sinus rhythm Body mass index ≤40 kg/m2 MRI contraindication : implanted defibrillator ; implant pacemaker devices/implants judgment investigator preclude MRI evaluation eGFR &lt; 30 mL/min/1.73 m2 Receiving incretin therapy ( DPP4 inhibitor , GLP1 mimetics ) , receive incretin therapy within previous 3 month screen Receiving therapy TZD receive TZD therapy within previous 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Saxagliptin</keyword>
	<keyword>Sitagliptin</keyword>
</DOC>